Overview
AVBP market data
Price History
AVBP price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$4.32 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.43 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $16.10 – $35.83 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.4B · P/B 2.70.
Company News
Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $40Benzinga · Aug 13, 2026, 8:23 PM
Guggenheim Reiterates Buy on ArriVent BioPharma, Maintains $45 Price TargetBenzinga · Aug 13, 2026, 2:24 PM
BTIG Reiterates Buy on ArriVent BioPharma, Maintains $42 Price TargetBenzinga · Aug 13, 2026, 10:14 AM
ArriVent BioPharma Q2 EPS $(1.05) Misses $(0.99) EstimateBenzinga · Aug 12, 2026, 8:17 PM
8-K filing — ArriVent BioPharma, Inc. (AVBP)SEC EDGAR · Aug 12, 2026, 8:07 PM
Truist Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $45Benzinga · May 29, 2026, 4:55 PM